Edition:
United Kingdom

Soleno Therapeutics Inc (SLNO.OQ)

SLNO.OQ on NASDAQ Stock Exchange Capital Market

1.74USD
18 Jan 2019
Change (% chg)

-- (--)
Prev Close
$1.74
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
13,179
52-wk High
$3.60
52-wk Low
$1.49

Latest Key Developments (Source: Significant Developments)

Abingworth LLP Says Soleno Therapeutics Represents Attractive Investment Based On Soleno's Business Prospects & Strategy
Thursday, 27 Dec 2018 

Dec 27 (Reuters) - Soleno Therapeutics Inc ::ABINGWORTH LLP SAYS SOLENO THERAPEUTICS REPRESENTS ATTRACTIVE INVESTMENT BASED ON SOLENO’S BUSINESS PROSPECTS & STRATEGY.ABINGWORTH LLP REPORTS 15.4% STAKE IN SOLENO THERAPEUTICS AS OF DECEMBER 21, 2018 - SEC FILING.  Full Article

Soleno Therapeutics Announces $16.5 Mln Private Placement
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS ANNOUNCES $16.5 MILLION PRIVATE PLACEMENT.SOLENO THERAPEUTICS INC - FUNDING TO SUPPORT ONGOING PHASE III CLINICAL PROGRAM (DESTINY PWS) FOR DCCR IN PRADER-WILLI SYNDROME.SOLENO THERAPEUTICS INC - ANDREW SINCLAIR WILL JOIN SOLENO'S BOARD OF DIRECTORS.  Full Article

Soleno Therapeutics Q3 Loss Per Share $0.13
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.11 FROM CONTINUING OPERATIONS.Q3 LOSS PER SHARE $0.13.CASH AND CASH EQUIVALENTS OF APPROXIMATELY $10.2 MILLION AT QUARTER-END.  Full Article

Soleno Therapeutics Receives Fast Track Designation From FDA For DCCR
Monday, 30 Jul 2018 

July 30 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS RECEIVES FAST TRACK DESIGNATION FROM FDA FOR DCCR FOR TREATMENT OF PRADER-WILLI SYNDROME.  Full Article

Soleno Therapeutics Q1 Loss Per Share $0.19
Wednesday, 16 May 2018 

May 16 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.17 FROM CONTINUING OPERATIONS.Q1 LOSS PER SHARE $0.19.  Full Article

Jack W. Schuler Living Trust Reports 13.4 Pct Stake In Soleno Therapeutics As Of December 15
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Soleno Therapeutics Inc ::JACK W. SCHULER LIVING TRUST REPORTS 13.4 PERCENT STAKE IN SOLENO THERAPEUTICS INC AS OF DECEMBER 15 - SEC FILING.  Full Article

Birchview Capital LP Reports A 6.17 Pct Passive Stake In Soleno Therapeutics
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Soleno Therapeutics Inc ::BIRCHVIEW CAPITAL LP REPORTS A 6.17 PCT PASSIVE STAKE IN SOLENO THERAPEUTICS AS OF DEC 15 - SEC FILING.  Full Article

Soleno Therapeutics Announces $15 Million Private Placement
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS ANNOUNCES $15 MILLION PRIVATE PLACEMENT.SOLENO THERAPEUTICS INC - SOLENO TO SELL 8.1 MILLION OF ITS COMMON SHARES AT $1.8425/SHARE.SOLENO THERAPEUTICS - TO USE PROCEEDS CONDUCT PLANNED PHASE III PROGRAM OF DIAZOXIDE CHOLINE CONTROLLED-RELEASE IN PRADER-WILLI SYNDROME.  Full Article

Soleno Therapeutics Announces Joint Venture Agreement For Commercialization Of Cosense Monitoring Technology
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS ANNOUNCES JOINT VENTURE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF COSENSE MONITORING TECHNOLOGY.SOLENO THERAPEUTICS INC - UNDER TERMS OF JV AGREEMENT, OAHL WILL INVEST UP TO $2.2 MILLION IN TRANCHES TO PURCHASE SHARES OF OUR CAPNIA SUBSIDIARY.SOLENO THERAPEUTICS INC - CAPNIA WILL NO LONGER BE A WHOLLY-OWNED SUBSIDIARY OF SOLENO.SOLENO THERAPEUTICS INC - UNDER TERMS OF JV AGREEMENT, GOING FORWARD, OAHL WILL BE RESPONSIBLE FOR FUNDING OPERATIONS OF CAPNIA.  Full Article

Soleno Therapeutics posts Q3 loss $0.24/shr from continuing operations
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Soleno Therapeutics Inc :Soleno Therapeutics provides corporate update and reports third quarter 2017 financial results.Q3 loss per share $0.24 from continuing operations.Q3 loss per share $0.35.  Full Article